Skip to main content
. 2011 Jun 2;6(6):e20598. doi: 10.1371/journal.pone.0020598

Figure 5. The efficacy of Sin/IL12 treatment is also dependent on NK cells.

Figure 5

(A) Left panel: FACS analysis of peritoneal samples from mock, Sin/LacZ, or Sin/IL12-treated ES-2-bearing mice shows the percentage of NK cells (CD122+ SSC low) within the CD45+ (immune cell) gate 48 h after the first of two daily Sin/LacZ or Sin/IL12 treatments. Data is representative of one experiment (n = 4). Right panel: kinetics of the change in peritoneal NK cell numbers in response to the treatment. Four time points (days 0/untreated, 1, 2, and 7) are shown (n = 2–4 for each time point). (B) The experiment shown in figure 4B and C was repeated, adding Sin/IL12-treated mice. NK cells were depleted with either anti-CD122 (middle panels) or anti-Asialo GM1 (right panels). Tumor growth and survival were monitored, quantified and plotted as in figure 4. Data is representative of one experiment (n = 3–4, as shown). Error bars represent SEM.